NED Biosystems is thrilled to announce the appointment to its Board of Directors of distinguished entrepreneur, investor, and global philanthropist, Yanchun “Lily” Li. Ms. Li brings an international strategic focus to the Board. Guided by her global vision and humanistic values, Ms. Li has decades of experience building bridges between business, academia, and humanitarian causes – creating meaningful impact. Her expertise will enhance NED’s ability to support cancer patients worldwide.
Ms. Li made history in 2005 for leading the first IPO of a mainland Chinese pharmaceutical company to IPO on the New York Stock Exchange (NYSE) with the company she co-founded, American Oriental Bioengineering [AOBO]. She was recognized as a “discoverer of the stock market” for her cross-border entrepreneurship.
Ms. Li is currently the Founder and Chairperson of Harvard Wealth Strategy & Management which provides strategy for investment between China and the U.S. Her experience advising founders and CEOs on IPOs, financings, mergers and acquisitions, and corporate restructuring is invaluable at this stage of NED’s development. In 2018, at the invitation of Ambassador Nicholas Burns (former U.S. Deputy Secretary of State and then current U.S. Ambassador to China), Ms. Li became an active contributor to Harvard University’s Future of Diplomacy Project, promoting research and dialogue on peace, leadership, and global security.
Previously, Ms. Li was on Harvard Kennedy School’s Dean’s Council, and a member of the Harvard Kennedy School of Government’s Women’s Leadership Board. Ms. Li currently serves as a Trustee of the International Vaccine Institute (IVI), supporting global health initiatives focused on equitable vaccine access and life sciences innovation.
Ms. Li’s appointment to NED’s Board of Directors supports NED’s mission as a Delaware Public Benefit Corporation to impact patients across the globe who currently lack access to care.
About NED Biosystems:
Based in Cambridge, Massachusetts, NED Biosystems is a clinical-stage biotech company focused on providing systems treatments for patients and their families. NED’s mission is to enable patients to achieve and sustain No Evidence of Disease. The Company’s novel platform has designed treatments to address large unmet needs for cancer and infectious disease patients. The Company’s goal is to develop treatments that achieve what today’s HIV treatments have: to transform what may be a death sentence diagnosis to No Disease, or reliably managed disease with quality of life.
NED’s novel platform pioneers a data-driven methodology. By simultaneously and redundantly affecting the processes driving disease, well-established by decades of research, treatments are designed to arrest disease progression and normalize disease-related imbalances. Deploying safe, evidenced-based agents lacking customary toxicity and side effects, NED’s treatments are comprehensive unlike today’s narrowly targeted therapies.
NED is a Delaware Public Benefit Company seeking to make its therapies accessible in both developed and developing countries.
For more information, visit https://nedbiosystems.com/.
For additional information regarding this press release, please contact info@nedbiosystems.com.
PHOTO links for media:
https://nedbiosystems.com/wp-content/uploads/2025/11/Li-Lily_website-e1762970718347.jpg
Caption: Lily Li, NED Biosystems’ New Director to the Board.
